Background: Tissue transglutaminase (tTG) immunoglobulin A (IgA) testing is a sen-
| INTRODUCTION
Tissue transglutaminase (tTG) immunoglobulin A (IgA) enzyme-linked immunosorbent assay testing is a highly sensitive adjunct for the diagnosis of coeliac disease. 1, 2 The antibodies are widely used in the management of coeliac disease and are incorporated in many of the guidelines promoted by professional societies. In particular, the tTG IgA assay is the preferred serology test for both diagnoses and follow-up during treatment. 3 It is typically undertaken at 6 months, 12 months, 24 months, and every other year thereafter. 3 While a persistently positive tTG test is predictive of ongoing damage in the intestine and likely gluten contamination, a negative tTG test has quite variable sensitivity for intestinal healing. [4] [5] [6] [7] [8] [9] Several different immunoassay kits exist to detect tTG antibodies, however, the sensitivity and cut-off for normal values can be kit-dependent. 10 At our facility, the assay used has the following tTG IgA reference values: <4 U/mL (negative); 4-10 U/mL (weak positive); and >10 U/mL (positive). These cut-offs were developed to maximise the diagnostic accuracy for the initial detection of coeliac disease and have not been designed or FDA cleared for monitoring the disease activity or predicting healing.
It has been our clinical observation that, within the negative range of the tTG assay, there may be a better prediction of mucosal healing with a result that is below the analytical measurement range (AMR), which is a tTG IgA <1.2 U/mL, whereas negative tests results above the detectable level (1.2-3.9 U/mL) may actually be more associated with residual or ongoing damage in the intestine. As such, the purpose of this study was to determine if an undetectable tTG
IgA level (<1.2 U/mL) can be more predictive of intestinal healing, and whether this was useful in guiding clinical decision-making during follow-up of coeliac disease.
| MATERIALS AND METHODS

| Population
A retrospective chart review study was performed using our internal coeliac disease registries as well as through the Advance Cohort TTG IgA levels of less than 1.2 U/mL were interpreted as being undetectable, while levels from 1.2-3.9 U/mL were considered detectable within the negative range (detectable).
| Clinical Symptoms
The presence of coeliac disease symptomology was obtained by review of the patients' chart during their follow-up visit after endoscopy and titre level. Symptoms included abdominal pain, nausea, bloating, fatigue, diarrhoea, bloody stool, steatorrhea and weight loss.
This was analysed as a binary value, either as symptomatic or not.
| Assessment of Histological Findings
Histology of duodenal biopsies were assessed using the Corazza- 
<24 mcg/L, female: <11 mcg/L), vitamin D (<25 ng/mL), Calcium (<8.9 mg/dL), Copper (<.75 mcg/mL) and Zinc ( <.66 mcg/mL).
| HLA Genotyping
The 
| Statistical Analysis
The tTG IgA results were categorised into two categories because results <1.2 U/mL were not reported on a continuous scale. A subset analysis was performed on patients on a gluten-free diet for 2 or more years. Logistic regression was used to assess the relation- and an alpha level of .05 was used to determine statistical significance.
3 | RESULTS
| Patient Demographics
A total of 402 patients were identified with our inclusion criteria ( 
| Presence of Symptoms in Relation to
Abnormal Biopsy
In patients who had a normal biopsy, 82 (48.2%) of 170 patients reported active symptoms as compared to 157 (67.7%) of 232 patients with an abnormal biopsy. In asymptomatic patients on a gluten-free diet for at least 6 months, the odds of having a normal biopsy was more than twice, 2.246 (CI: 1.494, 3.377; P<.001), the odds of symptomatic patients (Table 2 ). This increased odds ratio was seen again in asymptomatic patients who had been gluten free for at least 2 years (OR=2.171; CI: 1.331, 3.543; P=.002) (Table 3) .
| Persistent Mucosal Atrophy in Patients with
Negative tTG IgA Serology and Gluten Free for ≥2 Years
Duodenal histology was next separated on the basis of mucosal healing (Normal and Grade A) vs mucosal atrophy (Grade B1 + B2). 
| DISCUSSION
While the threshold for positivity in coeliac serology has been optimised for detection of disease, these same tests and thresholds are used clinically to monitor patients with treated coeliac disease. The purpose of this study was to determine if having a tTG IgA titre below the analytical measuring range was more predictive of healing, compared to negative titres which were almost within normal limits. Indeed, this study shows that there were differences in mucosal healing on follow-up biopsy when comparing patients with undetectable and detectable tTG IgA titres. Most importantly, undetectable tTG IgA titres were associated with increased mucosal healing when compared with patients with detectable serology.
Using tTG IgA serology is a sensitive method to identify active coeliac disease, 1,2 with some evidence suggesting that the diagnoses can be made without duodenal biopsy if titres are >62.5 U/mL. 16 However, when monitoring patients in follow-up, tTG IgA titres were poor indicators of mucosal healing, with sensitivities reported between 41% and 60%. [6] [7] [8] [9] Our work differs in that we looked at mucosal healing within a population with only negative follow-up tTG IgA titres. Due to the limitation of the serology kit used, our data were analysed categorically, and as such we were unable to identify an ideal cut-off limit. We were still able to detect significant differences in mucosal healing between patients with undetectable and detectable tTG-IgA. However, even having undetectable serology was not a good indicator for mucosal healing, as 51.2% this population was shown to have abnormal histology on follow-up biopsy.
Previous work involving a large Swedish patient cohort noted that 43% of coeliac disease patients still had persistent villous atrophy on duodenal histology at follow-up biopsy. Of these, (21%, 67/ 321) patients with seronegative disease as identified by antigliadin, antitissue transglutaminase, or antiendomysial antibodies still showed evidence of persistent villous atrophy. 17 In our study, 22.9% (44/ 192) of patients with undetectable titres still had evidence of villous atrophy after 2 years on a gluten-free diet. In comparison, there was evidence of villous atrophy in roughly 37.5% (33/88) of patients with titres in the detectable level of the negative range. The implications of this are unclear, as gradual mucosal healing has been shown to occur at the 1-2 year mark of coeliac disease, but does not appear to persist beyond 2 years from diagnosis. 18 However, these patients with residual villous atrophy at follow-up biopsy may benefit from focused dietetic intervention as described in the past. 9 We also investigated HLA genotyping for association with persistent duodenal villous atrophy. Though the HLA-DQB1*02,*02 genotype has been shown to have increased risk for coeliac disease, presence of HLA-DQB1*02 homozygosity was not associated with ongoing mucosal damage compared to HLA-DQB1 heterozygous patients.
Previous work investigating the utility of antibody serology as a marker for gluten-free compliance appears to have shown somewhat mixed results. In one study, 19 tTG antibody testing was shown to be a better marker for gluten-free compliance than intestinal biopsy.
However, further work into this question 6, 7 has shown that both tTG IgA and EMA IgA are poor indicators of both gluten-free compliance as well as intestinal mucosal healing. To account for possible effects of gluten on serology, patients in this study were excluded if noted to have deviated from a gluten-free diet. To further minimise factors that could affect serology levels, patients who had immunoglobulin deficiencies were excluded, as it had been previously shown tTG IgA titres were not found in IgA deficient coeliac disease patients. 20 Interestingly, recent work suggests that coeliac patients with only partial IgA deficiency may still show positive titres before initiation of a gluten-free diet. 21 Patients with active gastrointestinal symptoms were also noted to have an increased frequency of histological abnormalities on follow-up duodenal biopsies. Even at 2 years on a gluten-free diet, there was a trend towards statistical significance (.076, 22 However, persistent atrophy was not associated with any difference in haemoglobin, ferritin, vitamin B12 and copper.
There were some limitations to this study. First, the limitations of the kit used to measure tTg IgA hindered our ability to measure tTG IgA titres in a continuous fashion below the lowest measurable range of 1.2 assay units. As such, the possibility of the ideal IgA "cut-off" value could not be precisely identified. There could also be a bias as not all subjects who had a follow-up negative serology underwent a biopsy because their symptoms did not demand investigation. We could be under-representing the number of healed subjects since there was no reason for clinical biopsy. However, it is clinical practice at this institution to perform routine biopsies to monitor for mucosal healing in adults. Some of the patients studied were referred from outside institutions and had already been started on a gluten-free diet. As such, we sometimes did not have precise information on which serology was used for initial diagnosis. It is possible that some patients studied with persistent symptoms and mucosal damage evident despite having a tTG IgA of <1.2 may represent initially seronegative disease. However, we routinely tested for IgA deficiency. In terms of monitoring gluten-free compliance, this was done by reviewing clinical documentation during their follow-up visit after biopsy. However, no standardised diet history method was used, and adherence was based on the provider noting whether the patient remained on a strict diet or had knowingly consumed gluten. As such, more rigorous screening might have found more cases of noncompliance. The effect of this is unclear as the sensitivity of tTG IgA serology has been previously reported to be poor in assessing adherence. 6, 7 In conclusion, we have shown that in patients with treated coeliac disease and a tTG IgA titre within the negative reference range, having an undetectable level (<1.2 U/mL) is associated with having increased chance of intestinal mucosal healing compared to detectable titres (1.2-3.9 U/mL). We have also revealed that in patients with negative tTG-IgA titres, symptomatic patients are more likely to have evidence of histological abnormalities on duodenal biopsy. Due to the relatively small difference (OR of 1.956) between an undetectable and detectable titre, small bowel biopsy should still be considered during follow-up, especially if clinical symptoms are present.
